BioCentury | Jun 28, 2010
Finance

Banker Tracks

...healthcare investment banking. Awadalla was senior managing director and head of healthcare investment banking for FTN Equity Capital Markets...
BioCentury | Mar 8, 2010
Finance

Ebb & Flow

...Biren Amin joined WJB Capital as healthcare sector strategist. He was a biotech analyst with FTN Equity Capital Markets...
BioCentury | Feb 8, 2010
Finance

Venture Tracks

...a senior healthcare analyst with Westport Capital. First Horizon National shuttered its equity research business, FTN Equity Capital Markets...
BioCentury | Dec 7, 2009
Company News

Bio-Quant, NexMed deal

...end and is contingent on approval by Bio-Quant shareholders at their annual meeting in mid-December. FTN Equity Capital Markets...
BioCentury | Dec 7, 2009
Analyst Picks & Changes

Analyst Picks & Changes

...engager (BiTE) combines epitopes recognizing the CD3 and CD19 surface antigens. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) FTN Equity Capital Markets...
...hydrochloride, a broad spectrum non-competitive nicotinic receptor antagonist (see "Takeout letdowns..." A15). Theravance Inc. (NASDAQ:THRX) FTN Equity Capital Markets...
BioCentury | Oct 26, 2009
Analyst Picks & Changes

Analysts Picks & Changes

...FY10 estimated EPS to $2.46 from $2.51 on higher expected R&D expenses. Genzyme Corp. (NASDAQ:GENZ) FTN Equity Capital Markets...
BioCentury | Oct 5, 2009
Finance

Ebb & Flow

...49% of Sequenom shares held at June 30. Bank watch Point Capital Partners has acquired FTN Equity Capital Markets...
BioCentury | Jun 22, 2009
Finance

Ebb & Flow

...Swann as managing director and biotechnology analyst, covering mid- and large-cap biotechnology. Schimmer was with FTN Equity Capital Markets...
BioCentury | Jun 1, 2009
Analyst Picks & Changes

Analyst picks & changes

...in Tracleer bosentan's long-term sales potential in pulmonary arterial hypertension (PAH). AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) FTN Equity Capital Markets...
BioCentury | Feb 23, 2009
Finance

Ebb & Flow

...of days, the European indices are still 10% higher than their 52-week lows. Analyst tracks FTN Equity Capital Markets...
...biotech companies, was formerly with Davidson Kempner Capital Management, Cowen, and Deutsche Bank. Banker tracks FTN Equity Capital Markets...
Items per page:
1 - 10 of 10
BioCentury | Jun 28, 2010
Finance

Banker Tracks

...healthcare investment banking. Awadalla was senior managing director and head of healthcare investment banking for FTN Equity Capital Markets...
BioCentury | Mar 8, 2010
Finance

Ebb & Flow

...Biren Amin joined WJB Capital as healthcare sector strategist. He was a biotech analyst with FTN Equity Capital Markets...
BioCentury | Feb 8, 2010
Finance

Venture Tracks

...a senior healthcare analyst with Westport Capital. First Horizon National shuttered its equity research business, FTN Equity Capital Markets...
BioCentury | Dec 7, 2009
Company News

Bio-Quant, NexMed deal

...end and is contingent on approval by Bio-Quant shareholders at their annual meeting in mid-December. FTN Equity Capital Markets...
BioCentury | Dec 7, 2009
Analyst Picks & Changes

Analyst Picks & Changes

...engager (BiTE) combines epitopes recognizing the CD3 and CD19 surface antigens. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) FTN Equity Capital Markets...
...hydrochloride, a broad spectrum non-competitive nicotinic receptor antagonist (see "Takeout letdowns..." A15). Theravance Inc. (NASDAQ:THRX) FTN Equity Capital Markets...
BioCentury | Oct 26, 2009
Analyst Picks & Changes

Analysts Picks & Changes

...FY10 estimated EPS to $2.46 from $2.51 on higher expected R&D expenses. Genzyme Corp. (NASDAQ:GENZ) FTN Equity Capital Markets...
BioCentury | Oct 5, 2009
Finance

Ebb & Flow

...49% of Sequenom shares held at June 30. Bank watch Point Capital Partners has acquired FTN Equity Capital Markets...
BioCentury | Jun 22, 2009
Finance

Ebb & Flow

...Swann as managing director and biotechnology analyst, covering mid- and large-cap biotechnology. Schimmer was with FTN Equity Capital Markets...
BioCentury | Jun 1, 2009
Analyst Picks & Changes

Analyst picks & changes

...in Tracleer bosentan's long-term sales potential in pulmonary arterial hypertension (PAH). AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) FTN Equity Capital Markets...
BioCentury | Feb 23, 2009
Finance

Ebb & Flow

...of days, the European indices are still 10% higher than their 52-week lows. Analyst tracks FTN Equity Capital Markets...
...biotech companies, was formerly with Davidson Kempner Capital Management, Cowen, and Deutsche Bank. Banker tracks FTN Equity Capital Markets...
Items per page:
1 - 10 of 10